Medical condition
Leukemia
Leukemia is a medical condition tracked by NovaPharmaNews across 5 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- posaconazole (PHARMACOR POSACONAZOLE) Antiinfectives for systemic use (J02)
- zanubrutinib (BRUKINSA) Antineoplastic and immunomodulating agents (L01)
- exagamglogene autotemcel (CASGEVY) Blood and blood forming organs (B06)
- melphalan (ALKERAN) Antineoplastic and immunomodulating agents (L01)
- mercaptopurine (ALLMERCAP) Antineoplastic and immunomodulating agents (L01)
Latest Leukemia news
FDA Approves Orally Disintegrating Nilotinib (Cavhanza) for Chronic Myeloid Leukemia
The FDA has approved Cavhanza, an orally disintegrating tablet (ODT) formulation of nilotinib, for the treatment of select patients with chronic myeloid leukemia (CML). This new formulation enhances patient convenience by allowing co-administration with acid-reducing agents and reducing food-related burdens.
Laguna Biotherapeutics Receives FDA Clearance for LGNA-100 Pediatric Leukemia Trial
FDA clears Laguna's IND application for LGNA-100, a novel γδ T cell activator targeting high-risk pediatric leukemias, marking key regulatory milestone.
Mabwell's LILRB4/CD3 Bispecific Antibody 6MW5311 Receives NMPA IND Approval for Leukemia Treatment
Mabwell's innovative LILRB4/CD3 bispecific antibody 6MW5311 gets NMPA IND acceptance for AML and CMML treatment, marking a significant oncology milestone.
FDA Approves Bosulif for Pediatric Chronic Myelogenous Leukemia
Bosulif has received FDA approval for the treatment of pediatric chronic myelogenous leukemia, marking a significant advancement in pediatric oncology.